U.S.-UK alliance targets the world's deadliest superbugs

By Kate KellandLONDON (Reuters) - Eleven biotech companies and research teams in Britain and the United States were awarded up to $48 million in funding on Thursday to speed development of new antibiotics powerful enough to take on the world's deadliest superbugs.The range of antimicrobial medicines able to kill the growing number of drug-resistant infections is dwindling and health experts warn that within a generation the death toll from such "superbug" infections could reach 10 billion.Announ